Studies Immune In fi ltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors
暂无分享,去创建一个
J. Blay | N. Halama | P. Opolon | L. Zitvogel | G. Kroemer | P. Terrier | S. Bonvalot | A. Cesne | J. Coindre | A. Eggermont | N. Chaput | I. Cremer | J. Emile | P. Dubreuil | A. Concha | F. Garrido | C. Locher | N. Isambert | C. Flament | S. Rusakiewicz | V. poirier-colame | M. Sarabi | M. Semeraro | K. Chaba | L. Chaigneau | A. Caignard | R. Mendez | E. Desbois | E. Vimond | erie Le Brun-Ly | eric Commo
[1] Aki Vehtari,et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. , 2012, The Lancet. Oncology.
[2] C. Slingluff,et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. , 2012, Cancer research.
[3] R. Sciot,et al. Mitotic Checkpoints and Chromosome Instability Are Strong Predictors of Clinical Outcome in Gastrointestinal Stromal Tumors , 2011, Clinical Cancer Research.
[4] M. Heinrich,et al. Gastrointestinal stromal tumours: origin and molecular oncology , 2011, Nature Reviews Cancer.
[5] F. Bertucci,et al. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. , 2011, Cancer research.
[6] M. Pierotti,et al. Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy , 2011, Journal of Translational Medicine.
[7] Eric C. Sorenson,et al. Imatinib Potentiates Anti-tumor T Cell Responses in Gastrointestinal Stromal Tumor through the Inhibition of Ido Nih Public Access Author Manuscript , 2022 .
[8] P. Validire,et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. , 2011, Cancer research.
[9] L. Terracciano,et al. Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma , 2011, International journal of cancer.
[10] Jan Tavernier,et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors , 2011, Nature Medicine.
[11] M. Pierotti,et al. Targeted therapy in GIST: in silico modeling for prediction of resistance , 2011, Nature Reviews Clinical Oncology.
[12] M. Nykter,et al. Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors , 2011, Cancer.
[13] C. Antonescu,et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations , 2010, Proceedings of the National Academy of Sciences.
[14] J. Blay,et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. , 2010, The Lancet. Oncology.
[15] B. Rubin,et al. Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. , 2010, Gastroenterology.
[16] S. H. van der Burg,et al. Anti‐inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor‐treated gastrointestinal stromal tumors , 2010, International journal of cancer.
[17] J. Blay,et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity , 2010, Nature Medicine.
[18] A. Daneri-Navarro,et al. Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions , 2009, BMC Cancer.
[19] J. Blay,et al. Cell Cycle/Apoptosis Molecule Expression Correlates with Imatinib Response in Patients with Advanced Gastrointestinal Stromal Tumors , 2009, Clinical Cancer Research.
[20] J. Blay,et al. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. , 2009, Cancer research.
[21] C. Antonescu,et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.
[22] F. Haller,et al. Immune cells in primary gastrointestinal stromal tumors , 2008, European journal of gastroenterology & hepatology.
[23] G. Altavilla,et al. Natural killer cells infiltrating human nonsmall‐cell lung cancer are enriched in CD56brightCD16− cells and display an impaired capability to kill tumor cells , 2008, Cancer.
[24] P. Dubreuil,et al. The tyrosine kinase FES is an essential effector of KITD816V proliferation signal. , 2007, Blood.
[25] Masahiro Takada,et al. Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo , 2007, Breast Cancer Research and Treatment.
[26] H. Joensuu,et al. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. , 2006, Gastroenterology.
[27] P. Nelson,et al. Cytotoxic Markers and Frequency Predict Functional Capacity of Natural Killer Cells Infiltrating Renal Cell Carcinoma , 2006, Clinical Cancer Research.
[28] P. Opolon,et al. NK Cells Infiltrating a MHC Class I-Deficient Lung Adenocarcinoma Display Impaired Cytotoxic Activity toward Autologous Tumor Cells Associated with Altered NK Cell-Triggering Receptors1 , 2005, The Journal of Immunology.
[29] J. Blay,et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner , 2005, The Journal of experimental medicine.
[30] Y. Oda,et al. Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. , 2005, Human pathology.
[31] B. Nilsson,et al. Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era , 2005, Cancer.
[32] L. Sobin,et al. Gastrointestinal Stromal Tumors of the Stomach: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 1765 Cases With Long-term Follow-up , 2005, The American journal of surgical pathology.
[33] J. Blay,et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. , 2004, The Journal of clinical investigation.
[34] K. Wilson,et al. Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase* , 2004, Journal of Biological Chemistry.
[35] L. Larocca,et al. Role of p16/INK4a in gastrointestinal stromal tumor progression. , 2004, American journal of clinical pathology.
[36] Benoît Plancoulaine,et al. A simple way of quantifying immunostained cell nuclei on the whole histologic section , 2003, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[37] Samuel Singer,et al. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.
[38] G. Demetri,et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. , 2002, Human pathology.
[39] S. Lowe,et al. Dissecting p53 tumor suppressor functions in vivo. , 2002, Cancer cell.
[40] T. Jacks,et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications , 2001, Oncogene.
[41] D. Tuveson,et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.
[42] H. Anazawa,et al. Stem cell growth factor: in situ hybridization analysis on the gene expression, molecular characterization and in vitro proliferative activity of a recombinant preparation on primitive hematopoietic progenitor cells. , 2001, The hematology journal : the official journal of the European Haematology Association.
[43] K. Nakachi,et al. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population , 2000, The Lancet.
[44] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.